Stages of Drug Discovery and Development Process

Across the pharmaceutical industry there are several mandated processes that must be undergone
before the final sale of a drug can begin on the market. Following are the different stages which
are required to get approval of new drug for market authorization from Food and Drug
Administration (FDA).

1. Target identification
2. Target validation
3. lead identification
4. lead optimization
5. Product characterization
6. Formulation and development
7. Pre- clinical research
8. Investigational New Drug
9. Clinicaltrials
10. New Drug Application & Approval
 Stages of drug discovery and development process

1. Target Identification.

In the drug discovery process, target identification is the initial and critical phase where
researchers pinpoint a biological molecule, such as a gene, protein, enzyme, or receptor that
plays a pivotal role in a disease's development or progression. The primary objective is to
discover a drug-sensitive target that can be modulated by a therapeutic agent to treat, prevent,
or manage the disease effectively. This step is foundational, as selecting an inappropriate target
can lead to failures in subsequent development stages, resulting in significant resource and time
losses.

An ideal drug target should exhibit several key characteristics:

 Disease Relevance: It must be integral to the disease's pathology.

 Druggability: The target should be accessible and capable of interacting effectively with a
drug molecule.
 Specificity: Modulating the target should minimize effects on normal physiological
processes, reducing potential side effects.
  Measurable Activity: The target's activity should be quantifiable to facilitate assessment
during drug development.

To identify such targets, researchers employ various approaches:

1. Genomics and Bioinformatics: Utilizing computational tools to analyze genetic data,

identifying mutations or gene expressions associated with diseases.
2. Proteomics: Studying protein structures and functions to detect abnormalities linked to
disease states.
3. Pathway Analysis: Investigating biological pathways to uncover molecules that, when
modulated, can alter disease progression.
4. Phenotypic Screening: Empirically testing compounds in disease models to observe effects
and identify potential targets

2. Target validation.
Target validation is a critical phase in the drug discovery process that follows target identification.
It involves confirming that a biological molecule, such as a gene, protein, enzyme, or receptor, is
directly involved in a disease process and that modulating this target can produce a therapeutic
effect. This step ensures that the chosen target is not only associated with the disease but also
plays a causative role, making it a viable candidate for drug development.

The importance of target validation lies in its ability to increase the likelihood of clinical success.
By thoroughly validating a target, researchers can establish a clear connection between target
manipulation and disease modification, thereby reducing the risk of late-stage failures in drug
development. This process typically takes between 2 to 6 months and involves a series of rigorous
experiments to demonstrate that interacting with the target will yield therapeutic benefits within
an acceptable safety margin.

Several approaches are employed in target validation:

i. Genetic Manipulation: Techniques such as gene knockout, knockdown, or overexpression

are used to assess the impact of altering the target gene on disease phenotypes. For instance,
using siRNA to silence a gene can help determine its role in disease progression.

ii. Pharmacological Intervention: Small molecules or biologics are utilized to modulate the
target's activity. Observing the resultant effects on disease models helps in understanding the
therapeutic potential of targeting the molecule.

iii. Use of Animal Models: Genetically engineered animals, such as transgenic mice, are studied
to observe how modifications in the target affect disease development and progression.
iv. Cell-Based Assays: In vitro studies using cultured cells help in elucidating the cellular
functions of the target and its role in disease mechanisms.

3. lead identification.

Lead identification is a pivotal phase in the drug discovery process, focusing

on pinpointing chemical compounds—referred to as "leads"—that exhibit the
potential to interact effectively with a biological target associated with a
disease. These lead compounds serve as the foundational structures for
subsequent optimization efforts aimed at enhancing their therapeutic efficacy
and safety profiles.

Sources of Lead Compounds:

A. Natural Products: Historically, nature has been a rich reservoir of

pharmacologically active compounds. Many drugs in clinical use today are
derived from natural sources or are synthetic analogues of natural
substances. For instance, the antimalarial drug quinine is isolated from
the bark of the cinchona tree, and methadone, used to treat opioid
dependence, is a structurally simpler analogue of the opioid analgesic
morphine.

B. Chemical Libraries: These are extensive collections of synthetic

compounds maintained by pharmaceutical companies and research
institutions. High-throughput screening (HTS) techniques are employed to
rapidly assess these libraries for compounds that exhibit activity against
specific biological targets. HTS enables the efficient identification of
potential leads from vast chemical spaces.

C. Computational Methods: Advancements in computational chemistry

and bioinformatics have revolutionized lead identification. In silico
techniques, such as molecular docking and virtual screening, allow
researchers to model interactions between compounds and targets,
predicting binding affinities and biological activities. Machine learning
algorithms further enhance this process by analyzing large datasets to
identify patterns and predict compound efficacy.

Methods of Lead Identification:

i. High-Throughput Screening (HTS): This method involves the rapid
testing of thousands to millions of compounds against a biological target
to identify those with desired activity. HTS is instrumental in discovering
initial "hits" that can be further evaluated and optimized.

ii. Structure-Based Drug Design (SBDD): Utilizing the three-dimensional

structure of a biological target, SBDD allows for the rational design of
molecules that fit precisely into the target's active site. This approach
enhances the specificity and potency of lead compounds.

iii. Fragment-Based Lead Discovery (FBLD): This strategy involves

screening low-molecular-weight compounds (fragments) that bind to
different parts of the target molecule. These fragments are then
chemically linked or optimized to develop potent lead compounds.

4. Lead optimization.
Lead optimization is a critical phase in the drug discovery process that follows lead identification.
During this stage, researchers refine and enhance lead compounds to improve their efficacy,
selectivity, and safety profiles, transforming them into viable drug candidates ready for clinical
trials.

Key Objectives of Lead Optimization:

i. Enhancing Potency and Selectivity: Modifying the chemical structure of lead compounds to
increase their activity against the target while minimizing effects on non-targets.

ii. Improving Pharmacokinetic Properties: Adjusting the compound to ensure optimal

absorption, distribution, metabolism, and excretion (ADME) characteristics, thereby
enhancing bioavailability and therapeutic effectiveness.

iii. Reducing Toxicity: Identifying and eliminating structural elements associated with adverse
effects to ensure safety.

Strategies and Techniques in Lead Optimization:

i. Structure-Activity Relationship (SAR) Analysis: Systematically modifying chemical structures

and assessing the impact on biological activity to identify features critical for function.

ii. Computational Methods: Utilizing in silico techniques such as molecular docking, molecular
dynamics simulations, quantitative structure-activity relationship (QSAR) models, and
machine learning to predict how changes affect target interaction and to streamline the
optimization process.

iii. High-Throughput Screening (HTS): Rapidly testing large libraries of compound variants to
identify those with desirable properties.

iv. Fragment-Based Lead Discovery (FBLD): Starting with small molecular fragments that bind
to the target and building upon them to develop more potent compounds.
5. Product Charaterization.
When any new drug molecule shows a promising therapeutic activity, then the molecule is
characterized by its size, shape, strength, weakness, use, toxicity, and biological activity. Early
stages of pharmacological studies are helpful to characterize the mechanism of action of the
compound.

6. Formulation and Development.

Formulation and development are critical stages in the drug development process, focusing on
transforming an active pharmaceutical ingredient (API) into a safe, effective, and stable medicinal
product suitable for patient use. This phase ensures that the drug is delivered in the appropriate
form, maintains its efficacy throughout its shelf life, and meets all regulatory standards.
Key Objectives of Formulation and Development:

i. Enhancing Drug Stability: Ensuring the API remains stable under various environmental
conditions to maintain its therapeutic efficacy over time.

ii. Optimizing Bioavailability: Designing formulations that maximize the drug's absorption in
the body, ensuring the desired therapeutic effect is achieved.

iii. Ensuring Patient Compliance: Developing user-friendly dosage forms (e.g., tablets, capsules,
liquids) that encourage adherence to prescribed treatment regimens.

iv. Scalability and Manufacturability: Creating formulations that can be consistently and
efficiently produced on a large scale.

Challenges in Formulation and Development:

i. Solubility Issues: Many APIs exhibit poor water solubility, leading to challenges in
bioavailability. Techniques such as particle size reduction, salt formation, or the use of
solubilizing agents are employed to address this.

ii. Stability Concerns: APIs may degrade due to factors like light, temperature, or humidity.
Stabilizers and appropriate packaging solutions are utilized to mitigate these effects.

iii. Regulatory Compliance: Formulations must meet stringent regulatory requirements,

necessitating thorough documentation and adherence to quality standards.

7. Pre-Clinical Testing.

Preclinical testing is a vital phase in the drug development process that occurs before clinical
trials involving human participants. This stage aims to evaluate the safety, efficacy, and
pharmacological properties of a drug candidate through laboratory (in vitro) and animal (in vivo)
studies. The primary objectives are to determine a safe starting dose for human trials and to
identify potential toxic effects.

Key Components of Preclinical Testing:

i. Pharmacokinetic (PK) Studies: These studies assess how the drug is absorbed, distributed,
metabolized, and excreted in the body. Understanding the drug's half-life and bioavailability
helps in designing appropriate dosing regimens.

ii. Pharmacodynamic (PD) Studies: These investigations explore the biochemical and
physiological effects of the drug, elucidating its mechanism of action and the relationship
between drug concentration and effect.

iii. Toxicology Studies: Evaluating the potential adverse effects of the drug on various organ
systems is crucial. These studies help identify toxic doses and possible side effects, ensuring
that only safe compounds proceed to human trials.

iv. In Vitro Studies: Laboratory experiments using cell cultures to assess the drug's biological
activity, cytotoxicity, and potential efficacy before moving to animal models.

v. In Vivo Studies: Animal studies provide insights into the drug's overall effects in a living
organism, including efficacy, metabolism, and potential toxicity.

Regulatory Considerations:

Preclinical studies must adhere to Good Laboratory Practice (GLP) guidelines to ensure data
integrity and reliability. Regulatory agencies, such as the U.S. Food and Drug Administration
(FDA), require comprehensive preclinical data before approving the initiation of clinical trials in
humans. This data forms the basis of an Investigational New Drug (IND) application, detailing the
drug's safety profile and justification for human testing.
8. The Investigtional New Drug Process (IND).

The Investigational New Drug (IND) process is a critical phase in drug development, serving as a
gateway between preclinical research and clinical trials involving human participants. This
process ensures that investigational drugs are safe for human administration and that clinical
studies are ethically and scientifically sound.

Purpose of the IND Process:

The primary objective of the IND process is to protect the rights and safety of human subjects
participating in clinical trials. It provides a regulatory framework for the systematic evaluation of
investigational drugs, ensuring that they are reasonably safe for initial use in humans and that
the proposed studies are designed to yield meaningful data.

Key Components of an IND Application:

i. Animal Pharmacology and Toxicology Studies: Preclinical data demonstrating the safety and
biological activity of the drug in animal models.
ii. Manufacturing Information: Details on the composition, manufacturer, stability, and
controls used for producing the drug substance and product.

iii. Clinical Protocols and Investigator Information: Comprehensive plans for proposed clinical
studies, including study design, methodology, and information about the qualifications of
clinical investigators.

9. Clinical Research.

Clinical trials are conducted in people (volunteer) and intended to answer specific questions
about the safety and efficacy of drugs, vaccines, other therapies, or new methods of using
current
treatments.

10. A New Drug Application and Approval.

The New Drug Application (NDA) is a pivotal step in the drug development process, serving as a
formal proposal for the approval of a new pharmaceutical for sale and marketing. This application
compiles comprehensive data from all stages of drug development to demonstrate the drug's
safety and efficacy for its intended use.
Key Components of an NDA:
i. Pre-clinical Data: Results from laboratory and animal studies that provide initial information
on the drug's safety profile.
ii. Clinical Trial Data: Detailed findings from human studies, including data from Phases I
through III, outlining the drug's effects, side effects, and overall efficacy.
iii. Manufacturing Information: Documentation of the drug's composition, stability, and the
manufacturing process to ensure consistent quality.
iv. Labeling Proposals: Drafts of the prescribing information, including dosage guidelines,
potential risks, and instructions for use.
NDA Review Process:
Upon submission, the regulatory authority—such as the U.S. Food and Drug Administration
(FDA) or the Central Drugs Standard Control Organization (CDSCO) in India—conducts a
thorough evaluation of the NDA. This review assesses the drug's safety, efficacy, labeling, and
manufacturing processes. The goal is to ensure that the drug provides benefits that outweigh its
risks and that it can be produced with high quality standards.
Approval Outcome:
If the NDA satisfies all regulatory requirements, the authority grants approval, allowing the drug
to enter the market. Post-approval, the drug undergoes Phase IV studies, also known as post-
marketing surveillance, to monitor long-term effects and ensure continued safety in the general
population.

Made by Jashanjit Singh

Central Drugs Standard Control Organization (CDSCO)
The Central Drugs Standard Control Organization (CDSCO) is the national regulatory authority of
India, responsible for ensuring the safety, efficacy, and quality of pharmaceuticals, medical
devices, and cosmetics. It functions under the Ministry of Health & Family Welfare and is
governed by the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945.

1. Organizational Structure of CDSCO

CDSCO operates under the Drugs Controller General of India (DCGI), who is responsible for
overseeing all regulatory activities related to pharmaceuticals and medical devices in India. The
structure of CDSCO includes:
Hierarchy of CDSCO
Drugs Controller General of India (DCGI) – Head of CDSCO.
CDSCO Headquarters (New Delhi) – The main office managing national drug regulation.
Zonal Offices (6) – Oversee regulatory enforcement in different regions.
Sub-Zonal Offices (4) – Assist zonal offices in regulatory tasks.
Port Offices (13) – Control the import/export of pharmaceuticals and medical devices.
Central Drug Testing Laboratories (7) – Conduct quality control tests on drugs and medical
devices.
Flowchart of CDSCO Organizational Structure
2. Functions of CDSCO
CDSCO plays a vital role in regulating and monitoring pharmaceuticals, medical devices, and
cosmetics in India.
a) Approval of New Drugs – CDSCO evaluates New Drug Applications (NDA) to assess safety and
efficacy before granting marketing authorization.
b) Clinical Trial Approval & Monitoring – CDSCO regulates clinical trials under the New Drugs
and Clinical Trials Rules, 2019 to ensure ethical conduct and participant safety.
c) Import & Export Regulation – It issues import/export licenses for pharmaceuticals, ensuring
compliance with international safety standards.
d) Pharmacovigilance & Adverse Drug Reaction (ADR) Monitoring – Through the
Pharmacovigilance Programme of India (PvPI), CDSCO monitors drug safety post-marketing.
e) Medical Device Regulation – The Medical Devices Rules, 2017, brought medical devices
under CDSCO's regulatory control.
f) Good Manufacturing Practices (GMP) Compliance – CDSCO ensures that pharmaceutical
companies follow Schedule M of the Drugs and Cosmetics Act, 1940, which defines GMP
standards.
g) Coordination with State Drug Authorities – CDSCO works with state drug regulators to
enforce uniform drug standards across India.
h) Quality Control & Testing – CDSCO operates seven Central Drug Testing Laboratories to
assess the quality of pharmaceutical products.

3. Rules & Regulations Under CDSCO

The Drugs and Cosmetics Act, 1940, and related rules govern the functioning of CDSCO.
Important regulations include:
a) Drugs and Cosmetics Rules, 1945 – Defines procedures for drug approval, manufacturing,
sale, and distribution.
b) New Drugs and Clinical Trials Rules, 2019 – Regulates the approval of new drugs, clinical
trials, and ethics committees.
c) Medical Devices Rules, 2017 – Established a separate framework for regulating medical
devices.
d) Schedule M (GMP Guidelines) – Lays down standards for pharmaceutical manufacturing to
ensure quality and safety.
e) Schedule Y (Clinical Trials Regulation) – Defines requirements for conducting clinical trials in
India.
f) Pharmacovigilance Programme of India (PvPI) – Aims to monitor adverse drug reactions
(ADR) and ensure drug safety.

4. Types of Applications Processed by CDSCO

CDSCO handles several applications related to drug approval, clinical trials, and import/export.
A. Drug Approval Applications
a) New Drug Application (NDA) – Required for introducing new pharmaceutical drugs in India.
b) Investigational New Drug (IND) Application – Submitted before starting clinical trials of an
unapproved drug.

c) Biological License Application (BLA) – Required for the approval of biological products like
vaccines, biosimilars, and gene therapies.
B. Clinical Trial Applications
a) Form CT-04 (Clinical Trial Permission) – Required before conducting a clinical trial in India.
b) Ethics Committee Registration (Form CT-02) – Approval for ethics committees overseeing
clinical trials.
C. Import & Export Applications
a) Form 10 & 11 (Import License for Drugs & Medical Devices) – Permission to import
pharmaceutical products.
b) Form 41 & 42 (Registration Certificate for Imported Drugs) – Required for marketing foreign
pharmaceutical products in India.
D. Other Applications
Fixed-Dose Combination (FDC) Approval – Required for marketing drugs with multiple active
ingredients.
Post-Marketing Surveillance Applications – For Pharmacovigilance reporting and safety updates
on approved drugs.
United States: Food and Drug Administration (FDA)
The Food and Drug Administration (FDA) is the regulatory authority of the United States
responsible for ensuring the safety, efficacy, and security of pharmaceuticals, biological products,
medical devices, food, and cosmetics. It operates under the U.S. Department of Health and
Human Services (HHS) and enforces laws related to drug regulation, ensuring that only safe and
effective products reach the market.

1. Organizational Structure of FDA

The FDA is headed by the Commissioner of Food and Drugs, who reports to the Secretary of
Health and Human Services. It has multiple centers and offices that regulate specific product
categories.
Hierarchy of FDA
Office of the Commissioner (OC) → Centers for Product Regulation → Field Operations &
Compliance Offices

Main Centers of FDA

a) Center for Drug Evaluation and Research (CDER) – Regulates pharmaceutical drugs
(prescription and over-the-counter).
b) Center for Biologics Evaluation and Research (CBER) – Oversees vaccines, blood products,
gene therapies, and biologics.
c) Center for Devices and Radiological Health (CDRH) – Regulates medical devices and
radiation-emitting products.
d) Center for Food Safety and Applied Nutrition (CFSAN) – Ensures food and dietary
supplement safety.
e) Center for Veterinary Medicine (CVM) – Regulates animal drugs and veterinary products.
f) Center for Tobacco Products (CTP) – Oversees tobacco product regulation.
g) National Center for Toxicological Research (NCTR) – Conducts scientific research on
toxicology and drug safety.

2. Functions of FDA
The FDA's primary role is to ensure public health protection through the regulation of
pharmaceuticals, medical devices, and food safety.
Key Responsibilities of FDA
a) Approval of New Drugs and Biologics – Evaluates the safety and efficacy of new
pharmaceuticals before granting market authorization.
b) Regulation of Clinical Trials – Reviews Investigational New Drug (IND) applications to permit
human clinical trials.
c) Ensuring Drug Safety & Pharmacovigilance – Conducts post-marketing surveillance through
the FDA Adverse Event Reporting System (FAERS).
d) Quality Control of Manufacturing – Enforces Good Manufacturing Practices (GMP) for drug
production.
e) Monitoring Medical Devices – Classifies and evaluates medical devices under the Medical
Device Amendments of 1976.
f) Regulating Food Safety & Dietary Supplements – Ensures compliance with the Food Safety
Modernization Act (FSMA).
g) Overseeing Biologics & Gene Therapy – Regulates vaccines, monoclonal antibodies, and
gene editing products.
h) Tobacco & E-Cigarette Regulation – Implements tobacco control policies under the Family
Smoking Prevention and Tobacco Control Act.
i) Enforcing Compliance & Product Recalls – Issues recalls, warnings, and penalties for non-
compliance.

3. Rules & Regulations Under FDA

The FDA operates under several key laws and regulations, ensuring strict control over drug and
medical product approvals.
a) Federal Food, Drug, and Cosmetic Act (FDCA), 1938 – The primary law governing drug
approval, safety, and labeling.
b) Public Health Service Act (PHSA), 1944 – Regulates biologics and vaccines.
c) Hatch-Waxman Act, 1984 – Establishes the Abbreviated New Drug Application (ANDA)
pathway for generic drugs.
d) Prescription Drug User Fee Act (PDUFA), 1992 – Allows the FDA to collect fees from drug
manufacturers to fund faster approval processes.
e) 21 CFR (Code of Federal Regulations) – Contains detailed FDA guidelines on manufacturing,
labeling, and clinical trials.
f) Biologics Control Act, 1902 – Regulates biological products and blood safety.

4. Types of Applications Processed by FDA

FDA handles multiple drug and medical product applications, depending on the type of product
and approval pathway.
A. Drug Approval Applications
a) New Drug Application (NDA) – Required for new pharmaceutical drugs before marketing.
b) Investigational New Drug (IND) Application – Submitted before conducting clinical trials in
humans.
c) Abbreviated New Drug Application (ANDA) – For generic drugs, proving bioequivalence to an
already approved drug.
d) Biologics License Application (BLA) – Needed for biological products like vaccines,
monoclonal antibodies, and gene therapy.
B. Medical Device Approval Applications
a) 510(k) Premarket Notification – Required for low-to-moderate risk medical devices to prove
they are equivalent to existing devices.
b) Premarket Approval (PMA) – Required for high-risk Class III medical devices.
c) Investigational Device Exemption (IDE) – Needed before conducting clinical studies on
medical devices.
C. Other Regulatory Applications
a) Over-the-Counter (OTC) Drug Approval – For non-prescription drugs.
b) Orphan Drug Designation – For drugs treating rare diseases, providing market exclusivity
benefits.
c) Emergency Use Authorization (EUA) – Allows the use of unapproved drugs or vaccines
during public health emergencies (e.g., COVID-19 vaccines).

5. FDA Approval Process for New Drugs

The FDA follows a structured pathway to review and approve new pharmaceutical drugs:
Step-by-Step Drug Approval Process
Preclinical Testing (Lab & Animal Studies) → IND Application Submission → Phase I Clinical
Trials (20-100 participants) → Phase II Clinical Trials (100-500 participants) → Phase III Clinical
Trials (1000-5000 participants) → NDA Submission & Review → FDA Approval & Post-Marketing
Surveillance (Phase IV)
Average Approval Time for New Drugs
a) Standard NDA Review: 10-12 months
b) Priority Review NDA: 6 months

European Union: European Medicines Agency (EMA)

The European Medicines Agency (EMA) is the regulatory authority of the European Union (EU)
responsible for the scientific evaluation, supervision, and monitoring of medicines for human and
veterinary use. It ensures that medicinal products are safe, effective, and of high quality before
being marketed in the EU. The EMA works with 27 EU member states, plus Norway, Iceland, and
Liechtenstein (European Economic Area - EEA).

1. Organizational Structure of EMA

a) The EMA operates under the European Commission and collaborates with national
regulatory authorities (NRAs) of EU member states.
b) Hierarchy of EMA
c) Management Board → Executive Director → Scientific Committees & Working Parties → EU
National Regulatory Authorities (NRAs)
d) Main Bodies of EMA
e) Management Board – Supervises EMA’s activities, sets budget, and ensures operational
transparency.
f) Executive Director – Leads the agency, manages daily operations, and implements decisions.
g) Scientific Committees – Evaluate and approve medicines based on safety and efficacy.
h) Working Parties & Expert Groups – Provide specialized guidance in areas like biologics,
pharmacovigilance, and quality control.
i) National Competent Authorities (NCAs) – Each EU member state has its own regulatory
agency that collaborates with EMA.
Flowchart of EMA Organizational Structure
Management Board → Executive Director → Scientific Committees → National Regulatory
Agencies

2. Functions of EMA
a) The EMA plays a key role in the scientific assessment and monitoring of medicines across the
EU.
b) Approval of New Medicines – Evaluates Marketing Authorization Applications (MAA) for new
drugs.
c) Coordination of Pharmacovigilance – Monitors drug safety post-approval through the
EudraVigilance system.
d) Clinical Trial Regulation – Supervises clinical trial applications across EU states.
e) Quality & Manufacturing Oversight – Enforces Good Manufacturing Practice (GMP) and
Good Clinical Practice (GCP) guidelines.
f) Scientific Advice & Guidelines – Provides regulatory guidance to pharmaceutical companies.
g) Orphan Drug Designation – Supports development of drugs for rare diseases.
h) Medical Device & Biologics Regulation – Collaborates with European Commission’s Medical
Device Coordination Group (MDCG).

3. Rules & Regulations Under EMA

a) The EMA enforces EU pharmaceutical laws to ensure a high standard of medicine regulation.
b) Regulation (EC) No. 726/2004 – Defines the centralized procedure for drug approvals.
c) Directive 2001/83/EC – Establishes a community code for medicinal products.
d) Clinical Trials Regulation (EU) No. 536/2014 – Regulates clinical trial applications in the EU.
e) Pharmacovigilance Regulation (EU) No. 1235/2010 – Improves drug safety monitoring.
f) Medical Devices Regulation (MDR) (EU) 2017/745 – Establishes rules for medical device
approvals.

4. Types of Applications Processed by EMA

The EMA manages various regulatory applications for pharmaceuticals, biologics, and medical
devices.
A. Marketing Authorization Applications (MAA)
c) Centralized Procedure (CP) – Single application valid across all EU/EEA countries.
d) Decentralized Procedure (DCP) – Allows companies to apply in multiple EU countries
simultaneously.
e) Mutual Recognition Procedure (MRP) – An approved drug in one EU country can be
extended to others.
f) National Procedure (NP) – Approval granted only in a single EU member state.
B. Clinical Trial Applications (CTA)
Clinical Trials Regulation (CTR) Application – Required before conducting clinical trials in the EU.
C. Special Drug Designations
 Orphan Drug Designation (ODD) – For rare disease drugs (grants 10 years of market
exclusivity).
 Pediatric Investigation Plan (PIP) – Requires pharmaceutical companies to develop pediatric
medicines.

5. EMA Approval Process for New Drugs

The EMA follows a structured evaluation process for drug approval.

Step-by-Step Drug Approval Process

Preclinical Studies (Lab & Animal Research) → Clinical Trial Application (CTA) Submission → Phase
I (Safety Testing) → Phase II (Efficacy Testing) → Phase III (Large-Scale Testing) → Marketing
Authorization Application (MAA) Submission → EMA Approval & Market Launch
Timeline for Drug Approvals
i. Standard Review: 210 days
ii. Accelerated Review (Priority Drugs): 150 days

Australia: Therapeutic Goods Administration (TGA)

The Therapeutic Goods Administration (TGA) is the regulatory authority of Australia, responsible
for regulating therapeutic goods such as medicines, medical devices, blood products, and
biologicals to ensure their safety, efficacy, and quality. The TGA operates under the Department
of Health and Aged Care and enforces strict standards for pharmaceutical products before they
can be sold in the Australian market.

1. Organizational Structure of TGA

The TGA functions under the Australian Government Department of Health and Aged Care and is
responsible for ensuring compliance with therapeutic goods regulations.
Hierarchy of TGA
a) Minister for Health and Aged Care – Responsible for overall healthcare regulation in
Australia.
b) Secretary of the Department of Health and Aged Care – Supervises all regulatory agencies,
including TGA.
c) Deputy Secretary (Health Products Regulation Group) – Oversees TGA’s operations.
d) TGA Divisions:
e) Medicines Regulation Division – Approves and monitors prescription and non-prescription
drugs.
f) Medical Devices and Product Quality Division – Regulates medical devices and diagnostics.
g) Scientific Evaluation Division – Conducts assessments and clinical reviews of new therapeutic
goods.
h) Regulatory Engagement and Risk Management Division – Manages compliance and
enforcement.

2. Functions of TGA
The TGA regulates all therapeutic goods in Australia, ensuring they meet strict safety and efficacy
requirements.
a) Approval of New Drugs and Medical Devices – Evaluates applications for new medicines and
devices before market entry.
b) Clinical Trial Regulation – Grants approval for investigational medicines and oversees trial
safety.
c) Pharmacovigilance and Post-Market Surveillance – Monitors adverse events and recalls
unsafe products.
d) Licensing and GMP Compliance – Ensures manufacturers comply with Good Manufacturing
Practice (GMP) standards.
e) Regulation of Over-the-Counter (OTC) and Complementary Medicines – Manages vitamins,
herbal medicines, and dietary supplements.
f) Scheduling of Medicines and Poisons – Classifies drugs into different schedules based on risk
levels.

3. Rules & Regulations Under TGA

The TGA operates under the Therapeutic Goods Act 1989, which provides a legal framework for
regulating medicines, devices, and biologicals.
a) Therapeutic Goods Act 1989 – The primary law governing the regulation of therapeutic
goods in Australia.
b) Therapeutic Goods Regulations 1990 – Provides additional details on registration, licensing,
and labeling.
c) Good Manufacturing Practice (GMP) Guidelines – Ensures quality standards for
manufacturing pharmaceutical products.
d) Therapeutic Goods Advertising Code – Regulates how therapeutic products are promoted to
the public.
e) Poisons Standard (SUSMP - Standard for Uniform Scheduling of Medicines and Poisons) –
Classifies substances into different schedules based on their safety profile.

4. Types of Applications Processed by TGA

TGA manages applications for medicines, medical devices, and biologicals through different
approval pathways.
A. Drug Approval Applications
a) Prescription Medicine Registration (Category 1 & Category 2 Applications) – For new
chemical entities and major variations to existing medicines.
b) Over-the-Counter (OTC) Medicine Registration – For non-prescription medicines.
c) Complementary Medicine Listing – For vitamins, herbal products, and supplements under
the Listed Medicine (AUST L) category.
B. Clinical Trial Applications
a) Clinical Trial Notification (CTN) Scheme – Fast-track approval for clinical trials without direct
TGA assessment.
b) Clinical Trial Approval (CTA) Scheme – Required when the TGA must evaluate trial safety data
before initiation.
C. Medical Device & Biological Product Applications
a) Medical Device Registration (ARTG Inclusion) – Approval for Class I, II, III, and IV medical
devices.
b) Biological Product Approval – Required for cell and tissue-based therapies, blood products,
and vaccines.

5. TGA Approval Process for New Medicines

The TGA follows a step-by-step evaluation process before approving a new medicine for the
Australian market.
Step-by-Step Approval Process
Preclinical Research (Laboratory & Animal Studies) → Clinical Trial Application (CTN/CTA
Submission) → Phase I, II, III Clinical Trials → Marketing Authorization Submission (Category 1 or
2 Application) → TGA Evaluation & Approval → Post-Market Surveillance & Pharmacovigilance
Timelines for Approval
Standard Prescription Drug Review: 12-18 months
Priority Review Pathway: 6 months
Provisional Approval Pathway: Allows faster approval for drugs treating serious conditions
Japan: Ministry of Health, Labour and Welfare (MHLW)
The Ministry of Health, Labour and Welfare (MHLW) is Japan’s primary regulatory authority
responsible for overseeing public health, drug regulation, labour policies, and social welfare
programs. The MHLW works closely with the Pharmaceuticals and Medical Devices Agency
(PMDA) to ensure the safety, efficacy, and quality of pharmaceuticals, medical devices, and
biological products in Japan.

1. Organizational Structure of MHLW

The MHLW operates under the Japanese Government and is divided into multiple bureaus, each
responsible for specific regulatory functions.
Hierarchy of MHLW
i. Minister of Health, Labour and Welfare – Head of the MHLW, responsible for policy-making
and national healthcare regulation.
ii. Vice Minister & Parliamentary Secretaries – Support the Minister in administrative and
legislative matters.
iii. Bureaus & Agencies Under MHLW:
iv. Pharmaceuticals and Medical Devices Agency (PMDA) – Manages drug and medical device
approvals.
v. Health Policy Bureau – Develops national healthcare policies.
vi. Labour Standards Bureau – Regulates workplace safety and labour laws.
vii. Social Welfare and War Victims’ Bureau – Oversees welfare programs.
viii. Quarantine Stations – Control infectious diseases at ports and airports.
Flowchart of MHLW Organizational Structure
MHLW Headquarters → Bureaus (Health, Labour, Welfare, Pharmaceuticals, Quarantine, etc.) →
PMDA (Drug & Device Regulation)
2. Functions of MHLW
The MHLW plays a key role in Japan’s healthcare system by regulating pharmaceuticals, medical
devices, and public health policies.
i. Approval of New Drugs & Medical Devices – Reviews and approves applications for new
pharmaceuticals and medical devices.
ii. Regulation of Clinical Trials – Ensures ethical conduct and safety in human clinical studies.
iii. Pharmacovigilance & Drug Safety Monitoring – Oversees post-market surveillance to track
adverse drug reactions.
iv. Public Health & Disease Control – Implements national programs for infectious disease
control and vaccinations.
v. Labour & Employment Regulation – Manages workplace safety, working conditions, and
employment policies.
vi. Food & Cosmetics Safety – Regulates health supplements, food additives, and cosmetics.

3. Rules & Regulations Under MHLW

The MHLW enforces multiple laws and guidelines to regulate drugs, devices, and public health
policies.
a) Pharmaceuticals and Medical Devices Act (PMD Act) – Governs the approval and safety of
drugs and medical devices.
b) Good Manufacturing Practice (GMP) Guidelines – Ensures quality standards for
pharmaceutical manufacturing.
c) Good Clinical Practice (GCP) Guidelines – Regulates the conduct of clinical trials.
d) Food Sanitation Act – Ensures food safety standards and hygiene.
e) Labour Standards Act – Defines rules for employment, wages, and working hours.
Act on Securing Quality, Efficacy, and Safety of Pharmaceuticals, Medical Devices, etc. – Regulates
drug safety and post-market surveillance.

4. Types of Applications Processed by MHLW

The MHLW, through PMDA, handles regulatory applications for pharmaceuticals, medical
devices, and biological products.
A. Drug Approval Applications
a) New Drug Application (NDA) – For innovative new medicines.
b) Generic Drug Approval (GDA) – Required for marketing generic versions of approved drugs.
c) Biologics License Application (BLA) – For vaccines, gene therapy, and cell-based treatments.
B. Clinical Trial Applications
Investigational New Drug (IND) Application – For starting clinical trials in Japan.
C. Medical Device & Biological Product Applications
Class I Medical Device Notification – For low-risk medical devices.
Class II, III, IV Device Approval – For moderate to high-risk devices requiring PMDA evaluation.

5. MHLW Approval Process for New Medicines

The MHLW follows a structured review process for drug approval through the PMDA.
Step-by-Step Approval Process
Preclinical Studies (Lab & Animal Research) → Clinical Trial Approval (IND Submission) → Phase I,
II, III Clinical Trials → New Drug Application (NDA) Submission → PMDA Review & MHLW
Approval → Post-Market Surveillance & Safety Monitoring
Timelines for Approval
Standard Drug Review: 12-18 months
Priority Review (For Serious Conditions): 6 months
Canada: Health Canada
Health Canada is the national regulatory authority of Canada responsible for ensuring the safety,
efficacy, and quality of pharmaceuticals, medical devices, biologics, and natural health products.
It operates under the Minister of Health and regulates drug approvals, clinical trials, and public
health policies in Canada.
1. Organizational Structure of Health Canada
Health Canada operates through various directorates that oversee different aspects of drug and
medical product regulation.
Hierarchy of Health Canada
i. Minister of Health – Responsible for national healthcare policies and regulations.
ii. Deputy Minister of Health – Oversees all operational aspects of Health Canada.
iii. Health Products and Food Branch (HPFB) – Manages drug and medical product regulations.
iv. Therapeutic Products Directorate (TPD) – Regulates pharmaceutical drugs and medical
devices.
v. Biologic and Radiopharmaceutical Drugs Directorate (BRDD) – Oversees biologics, vaccines,
and gene therapies.
Natural and Non-Prescription Health Products Directorate (NNHPD) – Regulates natural health
products and OTC drugs.
Marketed Health Products Directorate (MHPD) – Monitors post-market drug safety and adverse
reactions.
Flowchart of Health Canada Organizational Structure
Minister of Health → Deputy Minister → Health Products and Food Branch (HPFB) → TPD, BRDD,
NNHPD, MHPD
2. Functions of Health Canada
Health Canada plays a crucial role in drug and medical device regulation to ensure public health
and safety.
i. Approval of New Drugs & Biologics – Evaluates safety and efficacy before market approval.
ii. Regulation of Clinical Trials – Ensures compliance with ethical and safety standards.
iii. Pharmacovigilance & Drug Safety Monitoring – Monitors adverse drug reactions through the
Canada Vigilance Program.
iv. Medical Device Regulation – Classifies and approves medical devices based on risk level.
v. Natural Health Products & OTC Drug Regulation – Ensures the safety of supplements, herbal
medicines, and over-the-counter products.
vi. Public Health & Disease Prevention – Implements national health policies, including
vaccination programs.
vii. Food & Cosmetic Safety Regulation – Ensures consumer product safety.

3. Rules & Regulations Under Health Canada

Health Canada enforces several laws and guidelines to regulate pharmaceuticals, medical
devices, and healthcare products.
i. Food and Drugs Act (FDA), 1920 – Governs the approval and regulation of drugs and medical
devices.
ii. Controlled Drugs and Substances Act (CDSA), 1996 – Regulates controlled substances and
narcotics.
iii. Canada Health Act, 1984 – Defines the principles of Canada's healthcare system.
iv. Good Manufacturing Practice (GMP) Guidelines – Ensures drug production quality.
v. Natural Health Products Regulations, 2004 – Regulates vitamins, herbal products, and
supplements.
vi. Medical Devices Regulations, 1998 – Defines safety requirements for medical devices.

4. Types of Applications Processed by Health Canada

Health Canada manages applications for pharmaceuticals, biologics, and medical devices through
different approval pathways.
A. Drug Approval Applications
New Drug Submission (NDS) – Required for new chemical entities and innovative medicines.
Abbreviated New Drug Submission (ANDS) – For generic drugs demonstrating bioequivalence.
Biologics License Application (BLA) – For vaccines, gene therapy, and biosimilars.
Over-the-Counter (OTC) Drug Registration – For non-prescription medications.
B. Clinical Trial Applications
Clinical Trial Application (CTA) – Required before initiating clinical trials in Canada.
Special Access Program (SAP) – Allows early access to unapproved life-saving drugs.
C. Medical Device Applications
Class I Device Registration – For low-risk devices (e.g., bandages, thermometers).
Class II, III, IV Medical Device Licenses – Required for moderate to high-risk devices.

5. Health Canada’s Drug Approval Process

The drug approval process in Canada follows a structured pathway to ensure safety and efficacy.
Step-by-Step Drug Approval Process
Preclinical Research (Lab & Animal Studies) → Clinical Trial Application (CTA) Submission → Phase
I, II, III Clinical Trials → New Drug Submission (NDS) Review → Health Canada Approval & Market
Launch
Timelines for Drug Approvals
Standard Review: 12-18 months
Priority Review (For Critical Drugs): 6 months